Clavis Pharma Successfully Completes Clinical Phase I Study in Haematology

Clavis Pharma has announced that an important milestone has been reached in its haematology program with ELACYT™.

ELACYT is in development for the treatment of haematological cancers (blood cancers) as well as for solid tumours.

The phase I part of the ongoing clinical phase I/II study within haematological cancers has been successfully completed.

The maximal tolerated dose (MTD) has been determined and clinical activity has been reported.

The phase II part will start when the dose and regimen has been decided by the international clinical expert group by the end of April 2008.

In this ongoing phase I/II study 75 patients have been treated to date and have tolerated ELACYT well at doses up to 2500 mg/m²/day.

Clavis Pharma ASA

Clavis Pharma ASA
Oncology drug development

Downloads

DownloadFull Press Release

Latest News

Baxter Announces Acquisition of Cheetah Medical

Baxter International Inc., a leading global medical products company, today entered into a definitive agreement to acquire Cheetah Medical, a leading provider of non-invasive hemodynamic monitoring technologies

Zipline announces positive results from two significant clinical studies

ZipLine Medical, Inc. has announced publication of positive results from two significant clinical studies in two peer- reviewed journals demonstrating that use of Zip® Surgical Skin Closure leads to better clinical outcomes and healthcare cost savings than do surgical staples

Valneva reports strong operational performance and major corporate progress with H1 2019 results

Valneva has reported that its H1 2019 results are marked by strong operational performance and major corporate progress; regaining control of key R&D assets and strengthening its financial outlook with $23 million CEPI chikungunya grant

Valneva initiates second Phase II study for its Lyme Disease vaccine candidate

Valneva has announced the initiation of the second study of Phase 2 clinical development for its leading, unique Lyme disease vaccine candidate VLA15

Valneva reports successful outcome of Phase 2 run-in for its Lyme disease vaccine candidate

Valneva SE has announced progress of its ongoing Phase 2 study for its leading, unique Lyme disease vaccine candidate, VLA15, into the main study phase

New data further validates Breast Cancer Index ability to predict extended endocrine therapy benefit

Biotheranostics, Inc. announces new pivotal data on the Breast Cancer Index that further validates its ability to accurately predict which women with early-stage, hormone receptor positive breast cancer will benefit from extended endocrine therapy